Insider Selling: Gyre Therapeutics (NASDAQ:GYRE) COO Sells 9,400 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 9,400 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $6.15, for a total value of $57,810.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at $4,305,000. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Weiguo Ye also recently made the following trade(s):

• On Thursday, May 21st, Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total value of $78,843.00.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock traded down $0.12 during mid-day trading on Friday, reaching $6.06. The stock had a trading volume of 86,973 shares, compared to its average volume of 90,296. The firm has a market capitalization of $588.00 million, a PE ratio of -67.33 and a beta of 2.03. Gyre Therapeutics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $11.61. The stock’s 50-day simple moving average is $7.29 and its 200-day simple moving average is $7.61.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The company had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million. On average, research analysts forecast that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings cut shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $38,000. Bank of America Corp DE increased its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares during the period. JPMorgan Chase & Co. lifted its stake in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in shares of Gyre Therapeutics in the fourth quarter worth $77,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.